gms | German Medical Science

66th Annual Meeting of the German Society of Neurosurgery (DGNC)
Friendship Meeting with the Italian Society of Neurosurgery (SINch)

German Society of Neurosurgery (DGNC)

7 - 10 June 2015, Karlsruhe

Article

Send article

Epithelial membrane protein 3 expression is a strong prognostic marker in anaplastic astrocytomas

Meeting Abstract

Search Medline for

  • Florian Stockhammer - Klinik für Neurochirurgie, Universitätsmedizin Göttingen
  • Arne Christians - Schwerpunktprofessur Neuropatholoie, Pathologisches Institut, Medizinische Hochschule Hannover
  • Antonia Horowski - Klinik für Neurochirurgie, Universitätsmedizin Göttingen
  • Stefan Pusch - Klinischen Kooperationseinheit Neuropathologie, Deutsches Krebsforschungszentrum, Heidelberg
  • Andreas von Deimling - Abteilung Neuropathologie, Universitätsklinikum Heidelberg
  • Christian Hartmann - Schwerpunktprofessur Neuropatholoie, Pathologisches Institut, Medizinische Hochschule Hannover

Deutsche Gesellschaft für Neurochirurgie. 66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC). Karlsruhe, 07.-10.06.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. DocDI.11.07

doi: 10.3205/15dgnc149, urn:nbn:de:0183-15dgnc1493

Published: June 2, 2015

© 2015 Stockhammer et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: The epithelial membrane protein 3 (EMP3) gene is located on 19q13.3 and, when methylated or engaged by allelic loss, is associated with favorable clinical course in oligodendroglial tumors. EMP3 is frequently hypermethylated in secondary, but rarely in primary glioblastomas. However, no data exist on the prognostic value of EMP3 protein expression in anaplastic astrocytoma and glioblastomas.

Method: Patient with first diagnosis of anaplastic astrocytoma and glioblastoma were eligible for this retrospective study. All patients received first line therapy by resection and adjuvant therapy. Immunohistochemical (IHC) staining with antibodies against EMP3 and IDH1 R132H were performed on tissue microarrays. Two investigators rated the IHC by consensus. Log rang test serves as survival comparison.

Results: 162 patients encompassing 21 anaplastic astrocytomas and 141 glioblastomas were included. EMP3 expression was associated with histology of glioblastomas and IDH1 wild-type (p<.0001, each). In patients with anaplastic astrocytoma 11 of 21 (52%) revealed staining for EMP3. Patients with anaplastic astrocytoma and lack of EMP3 expression revealed a favorable survival compared to patients with any EMP3 detection (median survival not reached vs. 50.5 month, p=.014). 5 years survival is 87 vs. 32%, respectively. The prognostic impact of EMP3 was stronger than age, IDH1 R132H expression and extent of resection. In glioblastomas EMP3 revealed no significant prognostic value.

Conclusions: EMP3 expression reveals an independent strong prognostic marker in anaplastic astrocytomas.